Tumor Immunology and Immunotherapy – Cellular Methods Part A

Lorenzo Galluzzi (Redaktør) ; Nils-Petter Rudqvist (Redaktør)

Tumor Immunology and Immunotherapy – Cellular Methods Part A, Volume 631, the latest release in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. Les mer
Vår pris
1863,-

(Innbundet) Fri frakt!
Leveringstid: Sendes innen 7 virkedager

Innbundet
Legg i
Innbundet
Legg i
Vår pris: 1863,-

(Innbundet) Fri frakt!
Leveringstid: Sendes innen 7 virkedager

Om boka

Tumor Immunology and Immunotherapy – Cellular Methods Part A, Volume 631, the latest release in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. New chapters include Detection of intracellular cytokine production by T cells with flow cytometry, High-throughput identification of human antigen-specific CD8+ and CD4+ T cells using soluble pMHC multimers, In vitro assays for effector T cell functions and activity of immunostimulatory antibodies, Ex vivo energetic profiling of tumor cells and T cells from mouse models and human samples, A cytofluorimetric assay to evaluate T cell polyfunctionality, and much more.

Fakta

Innholdsfortegnelse

1. Cytokine profiling of tumor-infiltrating T lymphocytes by flow cytometry Jeremy B. Foote, Sujith Sarvesh and Leisha A. Emens 2. High-throughput identification of human antigen-specific CD8+ and CD4+ T cells using soluble pMHC multimers Morgane Magnin, Philippe Guillaume, George Coukos, Alexandre Harari and Julien Schmidt 3. In vitro assays for effector T cell functions and activity of immunomodulatory antibodies Roberta Zappasodi, Sadna Budhu, Mohsen Abu-Akeel and Taha Merghoub 4. A cytofluorimetric assay to evaluate T cell polyfunctionality Belinda Palermo, Mariangela Panetta, Giulia Campo and Paola Nisticò 5. Assessment of memory formation by metabolically engineered antigen-specific CD8 T cells Mathias Wenes, Pedro Romero and Lianjun Zhang 6. Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models Mahmoud S. Alghamri, Felipe J. Núñez, Neha Kamran, Stephen Carney, David Altshuler, Pedro R. Lowenstein and Maria G. Castro 7. Methods to edit T cells for cancer immunotherapy Francesca Lucibello, Silvia Menegatti and Laurie Menger 8. Generating stem-like memory T cells with antioxidants for adoptive cell transfer immunotherapy of cancer Karolina Pilipow, Eloise Scamardella and Enrico Lugli 9. Reverse immunology: From peptide sequence to tumor-killing human T-cell clones Christophe Vanhaver, Monica Gordon-Alonso, Alexandre Bayard, Maria Teresa Catanese, Didier Colau, Pierre van der Bruggen and Annika M. Bruger 10. Generation of TCR-engineered reference cell samples to control T-cell assay performance Nicole Bidmon, Cécile Gouttefangeas and Sjoerd H. van der Burg 11. In vitro expansion of V?9Vd2 T cells for immunotherapy Christian Peters, Léonce Kouakanou, Hans-Heinrich Oberg, Daniela Wesch and Dieter Kabelitz 12. CFSE dilution to study human T and NK cell proliferation in vitro Iñigo Terrén, Ane Orrantia, Joana Vitallé, Olatz Zenarruzabeitia and Francisco Borrego 13. Rapid isolation and enrichment of mouse NK cells for experimental purposes Maite Alvarez, Maria C. Ochoa, Luna Minute, Ignacio Melero and Pedro Berraondo 14. Assessment of NK cell-mediated cytotoxicity by flow cytometry after rapid, high-yield isolation from peripheral blood Peter Holicek, Iva Truxova, Lenka Kasikova, Sarka Vosahlikova, Cyril Salek, Jana Rakova, Monika Holubova, Daniel Lysak, Isabelle Cremer, Radek Spisek and Jitka Fucikova 15. Two-dimensional dynamic evaluation of natural killer cell-mediated lysis of adherent target cells Alexandra Frazao, Louise Rethacker and Anne Caignard 16. Rapid isolation of mouse ILCs from murine intestinal tissues Kyle Burrows, Pailin Chiaranunt, Louis Ngai and Arthur Mortha 17. Detecting and analyzing murine innate lymphoid cells Alejandra Gomez-Cadena, Pedro Romero, Sara Trabanelli and Camilla Jandus 18. A cytofluorimetric assay to evaluate intracellular cytokine production by NK cells Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Segundo González and Alejandro López-Soto 19. Applications of microfluidic devices in advancing NK-cell migration studies Xiaoou Ren, Abdulaziz Alamri, Jolly Hipolito, Francis Lin and Sam K.P. Kung 20. Complementary approaches to study NKT cells in cancer Jay A. Berzofsky, Purevdorj B. Olkhanud and Masaki Terabe 21. Assessment of IFN-? and granzyme-B production by in "sitro" technology Claudia Galassi, Gwenola Manic, Martina Musella, Antonella Sistigu and Ilio Vitale 22. Assessment of IFN? responsiveness in patient-derived xenografts Jordan J. Cardenas, Camila Robles-Oteiza and Katerina Politi 23. Real-time cell analysis (RTCA) to measure killer cell activity against adherent tumor cells in vitro Hans-Heinrich Oberg, Christian Peters, Dieter Kabelitz and Daniela Wesch 24. Analysis of cancer cell-intrinsic immune regulation in response to CD8+ T cell attack Natalie J. Neubert, Laure Tillé, Christophe Martignier, Silvia A. Fuertes Marraco and Daniel E. Speiser 25. A flow cytometry-based method to screen for modulators of tumor-specific T cell cytotoxicity Javier Santos, Jesús Ogando, Rosa Ana Lacalle and Santos Mañes 26. Evaluation of NK cell cytotoxic activity against malignant cells by the calcein assay Seila Lorenzo-Herrero, Christian Sordo-Bahamonde, Segundo González and Alejandro López-Soto 27. 51Cr-release to monitor NK cell cytotoxicity Leslie Elsner and Ralf Dressel

Om forfatteren

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.

Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience. Nils-Petter Rudqvist received his M.Sc. (Physics, 2009) and Ph.D. (Medical Science, 2015) from the University of Gothenburg, Sweden. He decided to pursue an academic career and continue with his postdoctoral training in US. He first joined the Center for Radiological Research at Columbia University in New York where he studied gene signatures of radiation exposure. He then moved to Weill Cornell Medicine to join the program in radiation and immunity under the mentorship of Dr. Demaria. His current research is focused on investigating which neoantigens are key targets of the radiation-induced anti-tumor T cell response in mice and in patients treated with radiotherapy and immune checkpoint blockade. He recently demonstrated in a mouse model that radiation therapy diversifies the TCR repertoire of tumor infiltrating lymphocytes, an effect crucial for its synergy with immune checkpoint blockade treatment. Nils-Petter has also defined unique patters of expansion of TCR clonotypes in patients who respond or not to treatment with radiotherapy and ipilimumab. He has published 20 articles in peer-reviewed scientific journals and 60+ scientific conference abstracts.